Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03712813 · ClinicalTrials.gov registry record · NA

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors

A NA study of Breast Cancer, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
72
Enrollment target
1
Study location

NCT03712813 is a NA study of Breast Cancer that has completed, run by Indiana University. The registered enrollment target is 72 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03712813, a NA study of Breast Cancer, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control.

Conditions Studied

Interventions

  • DEVICE Macrodyne LivMD plate

Study Locations (1)

Indiana

  • Indiana University Melvin & Bren Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2019-10-02
Est. Completion 2025-12-18
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT03712813

The ClinicalTrials.gov registry entry for NCT03712813 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Macrodyne LivMD plate is the first listed.

NCT03712813 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT03712813 about?

NCT03712813 is a clinical study titled "Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors". The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer plann...

What is the current status of trial NCT03712813?

This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2019-10-02. Estimated completion is 2025-12-18.

What conditions does trial NCT03712813 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03712813?

The interventions under investigation include: Macrodyne LivMD plate (DEVICE).

Who is sponsoring clinical trial NCT03712813?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03712813 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.